Education
About Us
Working with TipRanks
Follow Us
OKYO Pharma Limited Sponsored ADR (OKYO)
NASDAQ:OKYO
OKYO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $1.90
Previous CloseN/A
Volume700.83K
Average Volume (3M)250.14K
Market Cap
$46.08M
Enterprise ValueN/A
Total Cash (Recent Filing)$627.56K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 05, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,886,314
10 Day Avg. Volume201,684
30 Day Avg. Volume250,140
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside414.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
OKYO Pharma Limited Sponsored ADR News
PremiumCompany Announcements
OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod
PremiumCompany Announcements
OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsOK-101 has demonstrated favorable safety and tolerability in a Phase 2 trial in dry eye disease, with statistically significant improvements in symptoms such as stinging/burning and ocular pain.
Regulatory ApprovalsOK-101 is the first NCP drug candidate that has received FDA IND clearance for clinical evaluation.
Bears Say
Financial RisksThe company needs to raise additional capital within the next 12 months to fund operations.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.04% Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors
OKYO FAQ
What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?
OKYO Pharma Limited Sponsored ADR lowest stock price was $0.81 and its highest was $1.90 in the past 12 months.
What is OKYO Pharma Limited Sponsored ADR’s market cap?
OKYO Pharma Limited Sponsored ADR’s market cap is $46.08M.
When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?
OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date is Aug 05, 2025 which is in 146 days.
How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?
OKYO Pharma Limited Sponsored ADR released its earnings results on Nov 29, 2024. The company reported -$0.09 earnings per share for the quarter, the consensus estimate of -$0.09 by $0.
Is OKYO Pharma Limited Sponsored ADR overvalued?
According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued.
Does OKYO Pharma Limited Sponsored ADR pay dividends?
OKYO Pharma Limited Sponsored ADR does not currently pay dividends.
What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?
OKYO Pharma Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?
OKYO Pharma Limited Sponsored ADR has 33,886,314 shares outstanding.
What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?
OKYO Pharma Limited Sponsored ADR reported an EPS of -$0.09 in its last earnings report, expectations of -$0.09. Following the earnings report the stock price went down -1.923%.
Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?
Currently, no hedge funds are holding shares in OKYO
---
OKYO Pharma Limited Sponsored ADR Stock Smart Score
Company Description
OKYO Pharma Limited Sponsored ADR
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
---
OKYO Stock 12 Month Forecast
Average Price Target
$7.00
▲(414.71% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Aldeyra Therapeutics
―
Ocular Therapeutix
―
Editas Medicine
―
Best Analysts Covering OKYO
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-7.51%
reiterated a buy rating 23 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -7.51% per trade.
---